gms | German Medical Science

27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

Deutsche Liga zur Bekämpfung des hohen Blutdrucks – Deutsche Hypertonie Gesellschaft e. V.

26. bis 29.11.2003, Bonn

Effects of Nebivolol, a Beta1-Selective Vasodilating Betablocker, on Exercise Performance and Body Mass Index

Wirkung von Nebivolol auf Leistungsfähigkeit und BMI

Meeting Abstract (Hypertonie 2003)

  • presenting/speaker A. Lichtenthal - Berlin-Chemie AG, Menarini Group (Berlin, D)
  • A. Marx - Berlin-Chemie AG, Menarini Group (Berlin, D)
  • B. Zegenhagen-Phiong - Berlin-Chemie AG, Menarini Group (Berlin, D)
  • S. Tegeler - Berlin-Chemie AG, Menarini Group (Berlin, D)
  • C. Milbredt - Berlin-Chemie AG, Menarini Group (Berlin, D)
  • R. Agrawal - Berlin-Chemie AG, Menarini Group (Berlin, D)

Hypertonie 2003. 27. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Bonn, 26.-29.11.2003. Düsseldorf, Köln: German Medical Science; 2004. Doc03hochP23

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hoch2003/03hoch123.shtml

Veröffentlicht: 11. November 2004

© 2004 Lichtenthal et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Introduction

Though betareceptor-blockers (BRB) are the drug of choice for many cardiovascular diseases, patients show a low compliance due to various known side-effects. Betablocker-therapy is commonly associated with a decrease of exercise performance (EP) and consecutively an increase of body mass index (BMI).

This observational multicenter study was performed to determine the effects of Nebivolol (Nebi) on EP and BMI.

Methods

6383 patients were included, 57% male, average age 55.9 years. Body weight was documented in 5951 patients exercise performance in 5808 patients after 3 and 6 weeks. The average bodyweight was 81.6 kg, body mass index 27.4. kg/m2.

Blood pressure reduction, heart rate and body weight were measured before treatment and 3 and 6 weeks after therapy. Exercise performance was defined as the walking distance of patients without complaints. The EP was subdivided into three groups: Group A-<100m; Group B-100-200 m; Group C->200 m.

Results

After 3 and 6 weeks of treatment with Nebi the average blood pressure was significantly reduced. The heart rate decreased from 81.4 to 72.0 b/min. The EP improved over the 6 week treatment period.

Before treatment 418 pts. were in Group A, 1043 in Group B and 4347 in Group C. After 3 weeks the distribution in the Groups A, B and C was 148, 778 and 4882 respectively. After 6 weeks 95, 437 and 5276 were in Group A, B and C.

The BMI before treatment was 81.5 ± 13.0, after 3 weeks 81.1 ± 12.9 and after 6 weeks 80.8 ± 12.7.

Conclusions

In this observational multi center study Nebivolol 5mg/d led to a reduction of blood pressure and heart rate. The exercise performance of patients improved after 3 and 6 weeks. BMI was not negatively influenced by treatment with Nebivolol. A possible explanation may be that an increased NO availability and thus increased exercise had the positive observed effects of Nebivolol.